Berdan, L.G.

patient trial event eptifibatide infarction stroke thrombocytopenia investigator pursuit platelet death study treatment 30 days table /iiia site investigators syndrome outcome group end-point baseline placebo therapy pursuit trial nonhemorrhagic stroke effect incidence enzyme glycoprotein elevation angina nonhemorrhagic population state end point treatment effect heparin model strategy point committee ischemic result heart site investigator califf rm revascularization ck-mb reduction intervention event rates circulation adjudication definition mahaffey infusion 72 hours swets subs service randomized topol ej assessment receptor percutaneou america events committee disagreement nadir review criteria count integrilin therapy enzyme elevations receptor suppression europe propensity score enrolment blood propensity adjudicated